Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma cell leukemia.

S R Hayman1, R Fonseca

  • 1Mayo Clinic, Department of Hematology, 200 First Street, SW, Rochester, MN 55905, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Plasma cell leukemia (PCL) is a rare, aggressive cancer. Treatment for primary PCL involves chemotherapy, but optimal regimens remain under investigation for this aggressive multiple myeloma variant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers.

Blood cancer journal·2026
Same author

Author Correction: ROBIN: Reference observatory of basins for international hydrological climate change detection.

Scientific data·2025
Same author

Experimental Observation of the Motion of Ions in a Resonantly Driven Plasma Wakefield Accelerator.

Physical review letters·2025
Same author

ROBIN: Reference observatory of basins for international hydrological climate change detection.

Scientific data·2025
Same author

Potential of accelerometer tags for monitoring of Japanese quail (<i>Coturnix japonica</i>) reproductive behaviour.

British poultry science·2024
Same author

Filamentation of a relativistic proton bunch in plasma.

Physical review. E·2024
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma (MM).
  • PCL has a fulminant course and poor prognosis, with median survival in months.
  • Disease presentation (de novo vs. secondary) impacts therapy and prognosis.

Purpose of the Study:

  • To summarize the characteristics and treatment approaches for plasma cell leukemia.
  • To highlight the challenges in managing primary PCL and the role of secondary PCL as a terminal event.

Main Methods:

  • Review of existing literature on plasma cell leukemia and multiple myeloma.
  • Analysis of prognostic factors and treatment outcomes based on disease presentation.

Main Results:

  • Secondary PCL is typically refractory to treatment, representing a terminal stage of MM.

Related Experiment Videos

  • Optimal treatment regimens for primary PCL are not well-established.
  • Recommended approach for eligible primary PCL patients includes induction chemotherapy followed by high-dose chemotherapy, ideally within a clinical trial.

    • Conclusions:

    • Plasma cell leukemia requires aggressive management strategies.
    • Further research is needed to establish optimal treatment protocols for primary PCL.
    • Clinical trials are crucial for advancing the treatment of this rare and aggressive hematologic malignancy.